Canaan Coker, MD
Neurology · Olathe, KSNPI 1205493723
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 201 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 16.3% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,247, more than ten times the $24 reported in 2019.
Across 201 payments — averaging $16.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$542
- Biogen$404
- EMD Serono, Inc.$304
- Lilly USA, LLC$249
- Pfizer$235
- Eisai Inc.$186
- plus $1K from 28 others
What the payments were for
- Food & beverage$3,318100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 44 | $542 |
| Biogen | 12 | $404 |
| EMD Serono, Inc. | 31 | $304 |
| Lilly USA, LLC | 10 | $249 |
| Pfizer | 29 | $235 |
| Eisai Inc. | 7 | $186 |
| Argenx US, Inc. | 7 | $145 |
| Neurocrine Biosciences, Inc. | 4 | $83 |
| Novo Nordisk | 3 | $80 |
| Lundbeck LLC | 4 | $78 |
| Acadia Pharmaceuticals Inc | 4 | $75 |
| Octapharma USA, Inc. | 3 | $72 |
| Sanofi | 3 | $69 |
| UCB, Inc. | 4 | $67 |
| Genentech USA, Inc. | 3 | $66 |
| TG Therapeutics, Inc. | 3 | $66 |
| Teva Pharmaceuticals USA, Inc. | 3 | $61 |
| Neurelis, Inc. | 3 | $56 |
| Vanda Pharmaceuticals Inc. | 3 | $53 |
| Globus Medical | 2 | $50 |
| Axsome Therapeutics, Inc. | 2 | $41 |
| Sandoz | 2 | $39 |
| SK Life Science, Inc. | 2 | $39 |
| Hospira, Inc. | 2 | $38 |
| Johnson & Johnson | 1 | $33 |
| Bristol Myers Squibb | 2 | $32 |
| Mallinckrodt Hospital Products Inc. | 1 | $28 |
| Boston Scientific | 1 | $24 |
| Jazz Pharmaceuticals Inc. | 1 | $24 |
| Abbott | 1 | $20 |
| Tanabe Pharma America, Inc. | 1 | $19 |
| Amneal Pharmaceuticals LLC | 1 | $17 |
| AstraZeneca | 1 | $14 |
| GSK | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- KISUNLA$119
How this compares
$3,318 in reported general payments places this provider in the 65th percentile of 131 neurology providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Carbidopa-LevodopaCarbidopa/Levodopa | 24 | $396 |
| Donepezil Hcl | 30 | $354 |
Paid to pharmacies, not to this prescriber.
Other neurology in Olathe
- Jay ZwibelmanOlathe$8K
- Ivan OsorioKansas City$101.7M
- Jeffrey KaplanLenexa$1.9M
- Rajesh PahwaKansas City$889K
- Sheetal MalikTopeka$137K
- Richard DubinskyKansas City$122K
- Barbara Jean OttleyHays$116K
- Jeffrey BurnsKansas City$115K
- Douglas DavisSalina$100K
- Amanda ThuringerKansas City$87K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.